Search

Your search keyword '"Lee, J.-E."' showing total 8 results
Start Over Author "Lee, J.-E." Journal british journal of cancer
8 results on '"Lee, J.-E."'

5. Phase II trial of imatinib mesylate in patients with metastatic melanoma

Author

Kim, K B, primary, Eton, O, additional, Davis, D W, additional, Frazier, M L, additional, McConkey, D J, additional, Diwan, A H, additional, Papadopoulos, N E, additional, Bedikian, A Y, additional, Camacho, L H, additional, Ross, M I, additional, Cormier, J N, additional, Gershenwald, J E, additional, Lee, J E, additional, Mansfield, P F, additional, Billings, L A, additional, Ng, C S, additional, Charnsangavej, C, additional, Bar-Eli, M, additional, Johnson, M M, additional, Murgo, A J, additional, and Prieto, V G, additional

Published
2008
Full Text
View/download PDF

7. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view

Author

Lim, D H, primary, Kim, D Y, additional, Kang, M K, additional, Kim, Y I, additional, Kang, W K, additional, Park, C K, additional, Kim, S, additional, Noh, J H, additional, Joh, J W, additional, Choi, S H, additional, Sohn, T S, additional, Heo, J S, additional, Park, C H, additional, Park, J O, additional, Lee, J E, additional, Park, Y J, additional, Nam, H R, additional, Park, W, additional, Ahn, Y C, additional, and Huh, S J, additional

Published
2004
Full Text
View/download PDF

8. A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells.

Author

Kim, H, Park, G-S, Lee, J E, and Kim, J-H

Subjects
LEUKOTRIENES, PACLITAXEL, BREAST cancer patients, DRUG resistance in cancer cells, P-glycoprotein, TUMOR growth
Abstract

Background:Breast cancer is the most common malignancy in women. Although chemotherapeutic agents, such as paclitaxel, are effective treatments for the majority of breast cancer patients, recurrence is frequent and often leads to death. Thus, there is an urgent need to identify novel therapeutic targets that sensitise tumour cells to existing chemotherapy agents.Methods:The levels of leukotriene B4 receptor-2 (BLT2) in multidrug-resistant MCF-7/DOX cells were determined using quantitative PCR and FACS analysis. The potential role of BLT2 in the paclitaxel resistance of MCF-7/DOX cells was assessed using a pharmacological inhibitor and small interfering RNA knockdown, and the BLT2-associated resistance mechanism was assessed.Results:The expression levels of BLT2 were markedly upregulated in MCF-7/DOX cells. The inhibition of BLT2 by pre-treatment with LY255283 or siBLT2 knockdown significantly sensitised MCF-7/DOX cells to paclitaxel and induced significant levels of apoptotic death, suggesting that BLT2 mediates paclitaxel resistance. We also demonstrated that BLT2-induced paclitaxel resistance was associated with the upregulation of P-glycoprotein. Finally, co-treatment with a BLT2 inhibitor and paclitaxel markedly reduced tumour growth in an MCF-7/DOX in vivo model.Conclusion:Together, our results demonstrate that BLT2 is a novel therapeutic target that sensitises drug-resistant breast cancer cells to paclitaxel. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results